Follicular Lymphoma Excellence Forum

Follicular Lymphoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Quiz

Measuring Risk of Therapy-Related Myeloid Neoplasms Among Patients With FL or DLBCL

11/06/2023

True or False: Findings from a 15-year SEER-Medicare study identified that prior histories of autoimmunity and the use of granulocyte colony-stimulating factors significantly decreased the risk of development of therapy-related...

True or False: Findings from a...

11/06/2023

Oncology

Videos

Mitigating Risk of Transformation Among Patients With Follicular Lymphoma

10/31/2023

Featuring Kiran Kumar, MD, MBA

Featuring Kiran Kumar, MD, MBA ...

Kiran Kumar, MD, MBA, discusses strategies for mitigating tumor burden and risk of transformation for patients with follicular lymphoma, particularly among those with early-stage or limited disease.

Kiran Kumar, MD, MBA, discusses...

10/31/2023

Oncology

Quiz

Epcoritamab Plus Rituximab and Lenalidomide for R/R FL

10/30/2023

True or False: The combination of epcoritamab plus rituximab and lenalidomide among patients with R/R follicular lymphoma demonstrated significantly high response rates, according to findings from the phase 1/2 EPCORE NHL-2 trial.

True or False: The combination...

10/30/2023

Oncology

Videos

Radiation Therapy for Patients With R/R Non-Hodgkin Lymphoma With Incomplete Response to CAR T-Cell Therapy

10/30/2023

Featuring Kiran Kumar, MD, MBA

Featuring Kiran Kumar, MD, MBA ...

Kiran Kumar, MD, MBA, explains study results regarding the potential benefits of re-priming radiation therapy among patients with R/R non-Hodgkin lymphoma, including FL and DLBCL, who experienced incomplete response after CD19-directed CAR...

Kiran Kumar, MD, MBA, explains...

10/30/2023

Oncology

Videos

Modifying Treatment Strategies for Patients With FL or DLBCL at Risk of Therapy-Related Transformation

10/30/2023

Featuring Abhay Singh, MD

Abhay Singh, MD, discusses the need for modifications in treatments for older patients with follicular lymphoma or DLBCL who are at risk of transformation to therapy-related myeloid neoplasms or acute myeloid leukemia.

Abhay Singh, MD, discusses the...

10/30/2023

Oncology

Quiz

Treating Follicular Lymphoma With Mosunetuzumab Monotherapy

10/24/2023

Updated results from the pivotal phase 2 GO29781 study on mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma demonstrated an overall response rate of approximately ___ among patients receiving this...

Updated results from the pivotal...

10/24/2023

Oncology

Videos

Evaluating Advances in the Treatment Landscape for Patients With Follicular Lymphoma

09/22/2023

Featuring Matthew Matasar, MD

Matthew Matasar, MD, discusses upcoming studies and encouraging advances in the evolving treatment landscape for patients with follicular lymphoma.

Matthew Matasar, MD, discusses...

09/22/2023

Oncology

Videos

Updates on the Safety, Efficacy of Mosunetuzumab Therapy for Patients With R/R Follicular Lymphoma

09/22/2023

Featuring Matthew Matasar, MD

Matthew Matasar, MD, shares updated results from a pivotal phase 2 study on the efficacy and safety of mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma.

Matthew Matasar, MD, shares...

09/22/2023

Oncology

Videos

Choosing Treatment Options and Managing Toxicities for Patients With R/R Follicular Lymphoma

08/18/2023

Featuring Carla Casulo, MD

At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Carla Casulo, MD, summarizes the available treatment options for relapsed/refractory follicular lymphoma and options for managing various treatment-related toxicities.

At the 2023 Great Debates &...

08/18/2023

Oncology

Videos

Epcoritamab Plus Rituximab and Lenalidomide Regimen Demonstrates High Response Rates Among Patients With High-Risk Follicular Lymphoma

07/19/2023

Featuring Reid Merryman, MD

At the 2023 ASCO meeting, Reid Merryman, MD, shares data assessing the efficacy and safety of epcoritamab plus rituximab and lenalidomide among patients with R/R FL.

At the 2023 ASCO meeting, Reid...

07/19/2023

Oncology

Recent News

Commentary

Challenges of Managing FL: A Focus on PI3K Inhibitors and Next-Line Therapy

04/26/2020

Elizabeth Brem, MD, discusses some of the challenges with managing FL, focusing on the incorporation of PIK3 kinase inhibitors in the treatment of these patients.

Elizabeth Brem, MD, discusses...

04/26/2020

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology